[Opinion] Should the 90% CI for GMR be required to encompass 1 [RSABE / ABEL]

posted by bebac_fan – US, 2018-03-29 16:57 (1304 d 11:41 ago) – Posting: # 18617
Views: 8,449

Dear John

» So basically he's questioning the validity of FDA's 20% window on BE then...

Actually, I am questioning the validity of FDA's Swr scaled 10% window on BE for NTID.

If a GMR of 1.1 is clinically relevant (i.e. a test should be sensitive for this), and the NTID with a Swr of .22 will pass by ABE, this is a failure IMO.

Thanks,
BF

Complete thread:

Activity
 Admin contact
21,753 posts in 4,548 threads, 1,544 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Sunday 04:39 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5